DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Immuno-Oncology Strategic Insight - Multi-Indication And Market Size Analysis" report to their offering.
We estimate that the total IO market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan)
The main drivers of this growth will come from immune checkpoint inhibitors, which will have sales of approximately $10 billion in 2019, rising to $24 billion by 2024. The highest-selling IO drugs by 2024 will be Opdivo and Keytruda, both PD-1 inhibitors, with sales of approximately $10 billion and $7 billion, respectively. This is because these two drugs will be first-to-market in many indications, leapfrogging competition such as Roche's atezolizumab and AstraZeneca's durvalumab.
Key Questions Answered
- Development of IO Products has increased significantly in the past three years. Which IO approaches will be the most commercially successful? Which early-stage IO approaches show the most promise?
- Novel combinations will differentiate late-to-market entrants. Which combinations are the most promising for each cancer type? What strategies are IO developers utilizing to differentiate themselves in this crowded market? What collaborations and deals are the most promising?
- NSCLC, melanoma, and myeloma will have the greatest contributions to the IO market in 2019 and 2024. Which diseases are going to be the biggest contributors to the IO market. Which IO product will be the most commercially successful in each disease? Which clinical and commercial strategies are IO developers pursuing in each disease?
Key Findings
- Opdivo will be the biggest selling IO drug by 2024, with approval forecast in seven indications
- Keytruda will be the second biggest selling IO drug by 2024, with approval forecast in eight indications
- NSCLC, melanoma, and myeloma will have the greatest contributions to the IO market in 2019 and 2024
- Novel combinations will allow late-to-market entrants such as durvalumab to achieve significant sales
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 IO Development
4 Technology and Product Overview
5 Indication-Specific Analysis
6 Company Strategies
7 Appendix
For more information visit http://www.researchandmarkets.com/research/q2k4t8/immunooncology
